Completed

Ginkgo Biloba and Desmopressin for Bedwetting in Children

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Ginkgo Biloba oral tablet

+ Desmopressin Acetate 0.2 mg Tablets

+ Desmopressin like Placebo

Drug
Who is being recruted

Urogenital Diseases+9

+ Behavior

+ Mental Disorders

From 5 to 18 Years
+2 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: November 2024
See protocol details

Summary

Principal SponsorMenoufia University
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 2024

Actual date on which the first participant was enrolled.

The study focuses on finding effective treatments for children who experience bedwetting at night, a condition known as monosymptomatic nocturnal enuresis. This is a common issue, with varying prevalence as children grow older. Traditionally, treatment has involved using alarms or medications like desmopressin, which helps reduce urine production at night. However, the study aims to explore the potential benefits of using Ginkgo Biloba, a herbal supplement known for its ability to improve sleep patterns and other health benefits, as an alternative to desmopressin. In the study, children with bedwetting issues will receive either Ginkgo Biloba or desmopressin to assess which is more effective in managing their condition. The participants will likely take the treatments orally, as these are common forms for such medications. The effectiveness of the treatments will be measured by observing changes in the frequency of bedwetting episodes. This research could offer a new treatment option that may have fewer side effects compared to traditional medications.

Official TitleGinkgo Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis: A Randomized Prospective Study
NCT06771128
Principal SponsorMenoufia University
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

398 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 5 to 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesBehaviorMental DisordersBehavioral SymptomsEnuresisFemale Urogenital Diseases and Pregnancy ComplicationsUrination DisordersUrologic DiseasesElimination DisordersFemale Urogenital DiseasesMale Urogenital DiseasesNocturnal Enuresis

Criteria

1 inclusion criteria required to participate
all children with monosymptomatic nocturnal enuresis.

1 exclusion criteria prevent from participating
children with day and night wetting.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

4 intervention groups are designated in this study

25% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Patients in this group receive both Ginkgo Biloba and desmopressin oral tablets.

Group II

Experimental
Patients in this group receive Ginkgo Biloba oral tablet.

Group III

Active Comparator
Patients in this group receive Desmopressin oral tablets.

Group IV

Placebo
Patients in this group receive Placebo oral tablet.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Menoufia Faculty of Medicine

Shebin El-Kom, EgyptOpen Menoufia Faculty of Medicine in Google Maps
CompletedOne Study Center
Ginkgo Biloba and Desmopressin for Bedwetting in Children | PatLynk